- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: Compound III is a survivin (BIRC5) inhibitor such as reported in patent US20110014192 A1 . Compound III is a potential nordihydroguaiaretic acid (NDGA)-based anti-neoplastic agent .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Ho SS, Go ML. (2013)
Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
Bioorg Med Chem Lett, 23 (22): 6127-33. [PMID:24080463]
2. Huang RC, Kimura K. (2011)
Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators.
Patent number: US20110014192 A1. Assignee: The Johns Hopkins University. Priority date: 08/01/2008. Publication date: 20/01/2011.